ALPHA-003

This program is in the pre-clinical phase.

The aim of this program is a drug to treat neurodegenerative diseases associated with the abnormal aggregation of the protein, tau, in brain cells. This encompasses the following diseases: Alzheimer’s disease, frontotemporal dementia, corticobasal degeneration, progressive supranuclear palsy, and chronic traumatic encephalopathy.

ALPHA-003 is built around the concept of preventing neuroinflammation from destabilising neuronal microtubules. This program involves ALPHA drugs designed to protect components of the cell’s cytoskeleton from responding to inflammatory ligands in a way that promotes microtubule instability.